NCT06685497 COLORECTUM+ Digital System for Postoperative Quality Improvement in Colorectal Cancer
| NCT ID | NCT06685497 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Colorectal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 236 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 236 participants in total. It began in 2024-12-01 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center, prospective, interventional study. A total of 236 colorectal cancer patients who underwent surgery will be enrolled and followed for 52 weeks. The digital healthcare quality management system, based on the COLORECTUM+ model, will be used for post-treatment quality evaluation and continuous improvement. Patients will be managed using an Internet+ post-treatment healthcare management platform. The platform integrates AI technology for real-time symptom analysis and alerts. Patients will report symptoms and health data through the platform, which will generate alerts based on symptom severity to guide appropriate interventions. Follow-up assessments will include patient adherence, satisfaction, quality of life, and healthcare utilization. The study expects to demonstrate that the digital healthcare quality management system improves follow-up rates, enhances patient adherence, reduces unplanned hospital visits, and increases overall patient satisfaction. The findings aim to provide evidence for the implementation of digital management systems in colorectal cancer post-treatment care, potentially leading to improved long-term outcomes for patients.
Eligibility Criteria
Inclusion Criteria: * Over 18 years old. * Pathologically confirmed colorectal cancer patients. * Underwent surgery at the Colorectal Cancer Diagnosis and Treatment Center, Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine. * Signed informed consent form. Exclusion Criteria: * Unable to access electronic devices that can connect to the internet or mobile communications. * Uncontrolled psychiatric illness. * The ECOG score is greater than or equal to 3. * Deemed unsuitable for participation by the investigator.
Contact & Investigator
Jun Qin
PRINCIPAL INVESTIGATOR
RenJi Hospital
Frequently Asked Questions
Who can join the NCT06685497 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06685497 currently recruiting?
Yes, NCT06685497 is actively recruiting participants. Contact the research team at wangxm0109@163.com for enrollment information.
Where is the NCT06685497 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06685497 clinical trial?
NCT06685497 is sponsored by RenJi Hospital. The principal investigator is Jun Qin at RenJi Hospital. The trial plans to enroll 236 participants.